Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
|Articles|September 28, 2021
- September 2021
- Volume 87
- Issue 9
September 2021 Pet Peeves
How would you respond to these situations?
Advertisement
Interrupted: Customers who yell over the customer you are helping to ask where something is.
Last Minute Requests: When people don't call ahead for items on the floor.
Supply and Demand: Asking if we have extra COVID-19 shots at 8am.
What's Bothering You? Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We'll share them here and online.
Articles in this issue
about 5 years ago
Case Studies: September 2021about 5 years ago
OTC Case Studies: Diabetesabout 5 years ago
Help Ensure Proper Medication Storage and Disposalabout 5 years ago
Call the Shots on Travel Vaccinesabout 5 years ago
September 2021 Rx Product Newsabout 5 years ago
Innovative Technology Helps Manage Chronic Conditionsabout 5 years ago
September 2021 OTC Product Newsabout 5 years ago
Research Third-Party Logistics Providers Beforehandabout 5 years ago
Help Patients Combat Dry EyeAdvertisement
Related to this article
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
4
Sotatercept in ERS PAH Guidelines: What Pharmacists Should Watch
5